Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	34.16	96.62	34.65	37.74	76.07
Short-Term Investments	136.97	189.36	22.9	13.59	-
Cash & Short-Term Investments	171.14	285.98	57.54	51.32	76.07
Cash Growth	-46.78%	396.98%	12.12%	-32.53%	-
Other Current Assets	3.79	4.62	3.12	1.93	1.02
Total Current Assets	174.93	290.6	60.66	53.25	77.09
Net Property, Plant & Equipment	6.32	10.66	10.61	12.44	7.81
Other Long-Term Assets	5.91	3.39	3.92	1.23	0.59
Total Assets	187.16	304.65	75.2	66.92	85.49
Accounts Payable	3.02	4.62	4.36	1.45	0.77
Accrued Expenses	27.17	25.19	12.58	8.23	8.34
Current Portion of Leases	3.69	3.94	2.92	2.28	0.81
Unearned Revenue	-	-	-	-	6
Total Current Liabilities	33.87	33.76	19.86	11.95	15.93
Long-Term Leases	1.34	4.3	6.16	8.29	4.74
Other Long-Term Liabilities	-	-	-	0.01	2.35
Total Long-Term Liabilities	1.34	4.3	6.16	8.29	7.09
Total Liabilities	35.21	38.06	26.02	20.25	23.02
Additional Paid-in Capital	538.94	530	4.64	1.71	0.53
Accumulated Other Comprehensive Income	0.03	0.11	0	-0.03	-
Retained Earnings	-387.02	-263.52	-136.04	-75.68	-46.78
Total Common Shareholders' Equity	151.95	266.59	-131.4	-74	-46.25
Minority Interest	-	-	180.57	120.67	108.72
Shareholders' Equity	151.95	266.59	49.18	46.68	62.47
Total Liabilities & Equity	187.16	304.65	75.2	66.92	85.49
Total Debt	5.02	8.24	9.08	10.56	5.56
Net Cash (Debt)	166.11	277.74	48.46	40.76	70.51
Net Cash Growth	-40.19%	473.08%	18.91%	-42.20%	-
Net Cash Per Share	3.84	7.25	71.94	89.48	0.27
Book Value	151.95	266.59	-131.4	-74	-46.25
Book Value Per Share	3.51	6.95	-195.06	-162.46	-0.17
Tangible Book Value	151.95	266.59	-131.4	-74	-46.25
Tangible Book Value Per Share	3.51	6.95	-195.06	-162.46	-0.17

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q